Zacks Investment Research downgraded shares of DOCTOR REDDYS (RDY) from OUTPERFORM to NEUTRAL on September 07, 2012, with a target price of $32.20.
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on DOCTOR REDDYS (RDY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment